At the news
? BULLISHIMPACT 6/10 8-K filed Nov 9, 2026 at 16:10 ET
GeneDx reported Q3 2026 revenue of $123.1M (+5% YoY) and adjusted EPS of $0.28, beating the $0.07 consensus. Exome and genome revenue grew 12% YoY to $110.4M on 25% volume growth. Full-year revenue guidance was reiterated at $475M-$490M, but exome and genome volume growth guidance was trimmed to at least 28% from at least 30%.
- Q3 2026 total revenue $123.1M, +5% YoY
- Exome and genome revenue $110.4M, +12% YoY
- Exome and genome volume 32,134, +25% YoY
- Adjusted diluted EPS $0.28 vs consensus $0.07
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access